Literature DB >> 19515018

Cellular and molecular biology of HCV infection and hepatitis.

Hengli Tang1, Henry Grisé.   

Abstract

HCV (hepatitis C virus) infects nearly 3% of the population worldwide and has emerged as a major causative agent of liver disease, resulting in acute and chronic infections that can lead to fibrosis, cirrhosis and hepatocellular carcinoma. Hepatitis C represents the leading cause of liver transplantation in the United States and Europe. A positive-strand RNA virus of the Flaviviridae family, HCV contains a single-stranded RNA genome of approx. 9600 nucleotides. The genome RNA serves as both mRNA for translation of viral proteins and the template for RNA replication. Cis-acting RNA elements within the genome regulate RNA replication by forming secondary structures that interact with each other and trans-acting factors. Although structural proteins are clearly dispensable for RNA replication, recent evidence points to an important role of several non-structural proteins in particle assembly and release, turning their designation on its head. HCV enters host cells through receptor-mediated endocytosis, and the process requires the co-ordination of multiple cellular receptors and co-receptors. RNA replication takes place at specialized intracellular membrane structures called 'membranous webs' or 'membrane-associated foci', whereas viral assembly probably occurs on lipid droplets and endoplasmic reticulum. Liver inflammation plays a central role in the liver damage seen in hepatitis C, but many HCV proteins also directly contribute to HCV pathogenesis. In the present review, the molecular and cellular aspects of the HCV life cycle and the role of viral proteins in pathological liver conditions caused by HCV infection are described.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19515018     DOI: 10.1042/CS20080631

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  45 in total

Review 1.  Vaccines to prevent infections by oncoviruses.

Authors:  John T Schiller; Douglas R Lowy
Journal:  Annu Rev Microbiol       Date:  2010       Impact factor: 15.500

2.  Functional evaluation of synthetic flavonoids and chalcones for potential antiviral and anticancer properties.

Authors:  Nelly Mateeva; Suresh V K Eyunni; Kinfe K Redda; Ucheze Ononuju; Tony D Hansberry; Cecilia Aikens; Anita Nag
Journal:  Bioorg Med Chem Lett       Date:  2017-04-13       Impact factor: 2.823

Review 3.  Direct-acting antiviral agents for hepatitis C virus infection.

Authors:  Jennifer J Kiser; Charles Flexner
Journal:  Annu Rev Pharmacol Toxicol       Date:  2012-11-05       Impact factor: 13.820

4.  Aberrant transcription and post-transcriptional processing of hepatitis C virus non-structural genes in transgenic mice.

Authors:  Mayura M Desai; Batbayar Tumurbataar; Yueqing Zhang; Lee-Nien Lillian Chan; Jiaren Sun; Teh-Sheng Chan
Journal:  Transgenic Res       Date:  2011-02-24       Impact factor: 2.788

Review 5.  New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy.

Authors:  Jing Tong; You-wei Wang; Yuan-an Lu
Journal:  J Zhejiang Univ Sci B       Date:  2012-01       Impact factor: 3.066

Review 6.  New insights into Nod-like receptors (NLRs) in liver diseases.

Authors:  Tao Xu; Yan Du; Xiu-Bin Fang; Hao Chen; Dan-Dan Zhou; Yang Wang; Lei Zhang
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2018-03-10

7.  Hepatitis C virus (HCV) interaction with astrocytes: nonproductive infection and induction of IL-18.

Authors:  Ziqing Liu; Fang Zhao; Johnny J He
Journal:  J Neurovirol       Date:  2014-03-27       Impact factor: 2.643

8.  Frontiers in the treatment of hepatitis C virus infection.

Authors:  Joseph Ahn; Steven L Flamm
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-02

Review 9.  A new insight into hepatitis C vaccine development.

Authors:  Chun I Yu; Bor-Luen Chiang
Journal:  J Biomed Biotechnol       Date:  2010-06-13

Review 10.  Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C?

Authors:  Youngmin A Lee; Scott L Friedman
Journal:  Antiviral Res       Date:  2014-04-12       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.